Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1 2016

Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1 2016
Published Jun 30, 2016
89 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1 2016, provides in depth analysis on Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1)
- The report reviews Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics

  
Source:
Document ID
GMDHC0212TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Overview81
Therapeutics Development94
  Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Products under Development by Stage of Development91
  Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Products under Development by Therapy Area101
  Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Products under Development by Indication112
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Pipeline Products Glance132
  Late Stage Products131
  Early Stage Products141
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Products under Development by Companies154
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Products under Development by Universities/Institutes192
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Therapeutics Assessment215
  Assessment by Monotherapy/Combination Products211
  Assessment by Mechanism of Action221
  Assessment by Route of Administration232
  Assessment by Molecule Type251
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Companies Involved in Therapeutics Development2612
  AbbVie Inc.261
  Amgen Inc.271
  Astex Pharmaceuticals, Inc.281
  CASI Pharmaceuticals Inc.291
  Merck &Co., Inc.301
  Millennium Pharmaceuticals, Inc.311
  Sanofi321
  Sareum Holdings Plc331
  Sigma-Tau S.p.A.341
  Taiho Pharmaceutical Co., Ltd.351
  Vertex Pharmaceuticals Incorporated361
  Vichem Chemie Research Ltd.371
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Drug Profiles3830
  alisertib Drug Profile385
  AMG-900 Drug Profile432
  AT-9283 Drug Profile452
  danusertib Drug Profile471
  ENMD-2076 Drug Profile486
  ilorasertib Drug Profile542
  MK-8745 Drug Profile561
  SAR-156497 Drug Profile571
  SAR-3 Drug Profile581
  SAR-4 Drug Profile592
  Small Molecule to Inhibit Aurora A Kinase for Oncology Drug Profile611
  Small Molecule to Inhibit Aurora A Kinase for Oncology Drug Profile621
  Small Molecules to Inhibit Aurora A Kinase for Oncology Drug Profile631
  Small Molecules to Inhibit Aurora A/B Kinase for Oncology Drug Profile641
  ST-5589 Drug Profile651
  TAS-119 Drug Profile661
  VE-465 Drug Profile671
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Dormant Projects689
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Discontinued Products772
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Featured News &Press Releases799
  Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma791
  May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC)791
  Nov 08, 2015: Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference791
  Nov 05, 2015: Poster For ENMD-2076 Phase 2 Trial In Soft Tissue Sarcoma Presented At The 2015 Connective Tissue Oncology Society Annual Meeting801
  Nov 04, 2015: CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma811
  Oct 14, 2015: CASI Pharmaceuticals Receives EU Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma Including Fibrolamellar Carcinoma821
  Sep 15, 2015: US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors821
  Jun 04, 2015: CASI Files New Drug Clinical Trial Application With China FDA To Expand U.S. Development Of ENMD-2076 In Fibrolamellar Carcinoma821
  May 12, 2015: Takeda Announces Termination of Alisertib Phase 3 Trial in Relapsed or Refractory Peripheral T-cell Lymphoma831
  Mar 30, 2015: CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma831
  Mar 25, 2015: CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China841
  Feb 09, 2015: CASI Pharmaceuticals Announces Receipt Of Final Minutes From FDA Meeting Regarding Clinical And Regulatory Path Of ENMD-2076 For Fibrolamellar Carcinoma841
  Dec 17, 2014: CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma851
  Nov 12, 2014: CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Soft Tissue Sarcoma861
  Jul 21, 2014: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China862
Appendix882
  Methodology881
  Coverage881
  Secondary Research881
  Primary Research881
  Expert Panel Validation881
  Contact Us881
  Disclaimer891

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Aurora-Kinase-A-Serine-Threonine-Protein-Kinase-15-or-Aurora-IPL1-Related-Kinase-1-or-Aurora-2-or-EC-2-7-11-1-Pipeline-Review-H1-2016-2088-16102>
  
APA:
Global Markets Direct - Market Research. (2016). Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Aurora-Kinase-A-Serine-Threonine-Protein-Kinase-15-or-Aurora-IPL1-Related-Kinase-1-or-Aurora-2-or-EC-2-7-11-1-Pipeline-Review-H1-2016-2088-16102>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.